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Although the improvement of coronary stents and medical 
agents has reduced adverse cardiac events in patients 
undergoing percutaneous coronary intervention (PCI), stent 
thrombosis (ST) still remains one of fatal complications 
of stent therapy. However, the pathophysiology of ST 
has not been sufficiently established yet, and factors 
including comorbidities such as diabetes mellitus, stent 
design, and patients’ response or adherence to antiplatelet 
therapy have had the association with ST occurrence (1,2). 
Recently, a large prospective registry study investigating 
the intravascular morphologies of coronary stents in 
patients suffering from ST was published (3). Using optical 
coherence tomography (OCT) that had higher resolution 
than intravascular ultrasound, the study demonstrated the 
underlying mechanisms of ST, helping to guide the ST 
treatment (3). In this article, ST-related factors focusing on 
coronary stents are discussed.
Stent malapposition and under-expansion
Stent malapposition is defined as separation of at least 1 stent 
strut from the intimal surface of the arterial wall that is not 
overlapping a side branch (4). Because these floating struts 
are associated with delayed healing after stent implantation, 
especially drug-eluting stent (DES), malapposed stents have 
been considered as a potential risk for the development of ST. 
However, clinical data about stent malapposition have been 
controversial. In intravascular ultrasound study investigating 
the long-term prognosis of late stent malapposition that 
was detected at 6 months after DES implantation, the stent 
malapposition was not associated with any major adverse 
cardiac events during a subsequent 10-month follow-up (4). 
A similar finding was observed in an OCT study, in which 
adverse cardiac events did not occur in patients with late 
stent malapposition during follow-up of mean 28 months 
after DES implantation (5). Contrary to these studies, cross-
sectional OCT studies showed that the malapposition was 
a leading cause of early, late, or very late ST (3,6). These 
discrepancies were partly explained by the finding that stent 
malapposition could be spontaneously resolved over time (5,7). 
As a determinant for the resolution of stent malapposition, 
the distance between malapposed strut and vessel wall was 
proposed: the greater the distance, the more persistent 
the malapposition (8). In the study by Souteyrand et al., 
the average maximal malapposition distance was 710 μm, 
indicating the severe malapposition (3).
Factors causing stent malapposition are multifactorial. 
During stent implantation, malapposition can occur for 
stent under-expansion, or appear for follow-up period due 
to positive vascular remodeling of stented lesion. In some 
cases presented with acute coronary syndrome, thrombus 
between struts and vascular wall may spontaneously dissolve, 
causing the malapposition. However, the important thing 
here is that inadequately expanded stent during PCI can be 
fully preventable using intravascular imaging modalities. 
Until recently, it has not been determined whether the 
routine usage of the imaging devices for PCI is beneficial or 
not. Nevertheless, the usefulness of intravascular imaging 
seems to be robust to achieve the optimal stent expansion, 
and to minimize large stent malapposition. Considering 
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the delayed healing of malapposed stents, the finding that 
stent malapposition and under-expansion were prominent 
mechanisms for early ST is not surprising.
Neoatherosclerosis
Emerging evidences have established that neoatherosclerosis, 
atherogenesis within neointima of implanted coronary 
stent, is one of mechanisms causing late stent failure. 
According to the pathologic study, neoatherosclerosis 
was not rare, and could have unstable features such as 
thin cap or rupture of neointimal tissue (9). In several 
OCT studies, neoatherosclerosis was more identified 
in patients presented with acute coronary syndrome 
than in those with stable restenotic lesion, resulting 
in more target lesion revascularizations (10,11). Thus, 
neoatherosclerotic lesion could be manifested with wide 
spectrum from stable coronary artery disease to acute 
myocardial infarction including late or very late ST (12). 
This feature was also confirmed in ST registries, in which 
ruptured neoatherosclerosis, as well as stent malapposition, 
was a frequent OCT finding in patients suffering from 
late or very late ST (3,6). Although the pathophysiology 
of neoatherosclerosis has remained unknown, several 
OCT studies suggested that specific factors such as 
stent type, stent age, patients’ characteristics including 
current smoking, chronic kidney disease, usage of 
angiotensin-converting enzyme inhibitors/angiotensin II 
receptor blockade, and the concentration of low-density 
lipoprotein cholesterol were associated with the presence 
of neoatherosclerosis at follow-up (13-15). Accordingly, 
the continued medical  care for the inhibit ion of 
neoatherosclerosis may be warranted in patients receiving 
coronary stents.
Importantly, the OCT study from Souteyrand et al. 
revealed the underlying morphological abnormalities in 
most ST cases, introducing the possibility of patient-tailored 
therapy (3). For example, in ST resulting from malapposition, 
a simple balloon angioplasty may be sufficient to restore the 
coronary flow, and to attach malapposed struts to vascular 
wall. On the contrary, an additional stent implantation may 
be not beneficial without resolving the malapposition. In 
patients with neoatherosclerosis, a plain balloon angioplasty 
may be not appropriate to inhibit the future growth 
of neoatherosclerotic neointima. These individualized 
strategies, based on the mechanisms of ST occurrence, 
look reasonable, but it is not easy to prove the benefits of 
these approaches because the incidence of ST is quite low, 
requiring a large study population for screening. In the 
2011 ACCF/AHA/SCAI guideline for PCI, the treatments 
of patients presented with ST were not established, thus 
emphasizing the importance of ST prevention that included 
ensuring compliance with dual antiplatelet therapy and 
adequate stent sizing and expansion (16). However, given 
the poor prognosis of ST, it is necessary to consider the 
specific treatment strategy based on intravascular imaging 
in patients undergoing ST.
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